These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 36338689)

  • 1. The current role of secondary cytoreductive surgery for recurrent ovarian cancer.
    de Bree E; Michelakis D; Anagnostopoulou E
    Front Oncol; 2022; 12():1029976. PubMed ID: 36338689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytoreductive surgery followed by chemotherapy versus chemotherapy alone for recurrent platinum-sensitive epithelial ovarian cancer (SOCceR trial): a multicenter randomised controlled study.
    van de Laar R; Zusterzeel PL; Van Gorp T; Buist MR; van Driel WJ; Gaarenstroom KN; Arts HJ; van Huisseling JC; Hermans RH; Pijnenborg JM; Schutter EM; Pelikan HM; Vollebergh JH; Engelen MJ; Inthout J; Kruitwagen RF; Massuger LF
    BMC Cancer; 2014 Jan; 14():22. PubMed ID: 24422892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secondary cytoreductive surgery - viable treatment option in the management of platinum-sensitive recurrent ovarian cancer.
    Felsinger M; Minar L; Weinberger V; Rovny I; Zlamal F; Bienertova-Vasku J
    Eur J Obstet Gynecol Reprod Biol; 2018 Sep; 228():154-160. PubMed ID: 29957400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal chemotherapy treatment for women with recurrent ovarian cancer.
    Fung-Kee-Fung M; Oliver T; Elit L; Oza A; Hirte HW; Bryson P
    Curr Oncol; 2007 Oct; 14(5):195-208. PubMed ID: 17938703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival after secondary cytoreductive surgery and chemotherapy compared with chemotherapy alone for first recurrence in patients with platinum-sensitive epithelial ovarian cancer and no residuals after primary treatment. A registry-based study.
    Szczesny W; Langseth H; Myklebust TÅ; Kaern J; Tropé C; Paulsen T
    Acta Obstet Gynecol Scand; 2018 Aug; 97(8):956-965. PubMed ID: 29790149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Laparoscopic splenectomy both for primary cytoreductive surgery for advanced ovarian cancer and for secondary surgery for isolated spleen recurrence: feasibility and technique.
    Macciò A; Sanna E; Lavra F; Chiappe G; Petrillo M; Madeddu C
    BMC Surg; 2021 Oct; 21(1):380. PubMed ID: 34711237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secondary cytoreduction in recurrent ovarian cancer- experience from a tertiary care centre in India.
    Bhati P; Thomas A; George Chandy R; Datta A; Susan Thomas D; Thomas V; Peedicayil A; Sebastian A
    Gynecol Oncol Rep; 2024 Aug; 54():101463. PubMed ID: 39149126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Olaparib beyond progression compared with platinum chemotherapy after secondary cytoreductive surgery in patients with recurrent ovarian cancer: phase III randomized, open-label MITO 35b study, a project of the MITO-MANGO groups.
    Schettino C; Musacchio L; Bartoletti M; Chiodini P; Arenare L; Baldassarre G; Califano D; Capoluongo E; Costi MP; D'Incalci M; Marchini S; Mezzanzanica D; Normanno N; Scala S; Greggi S; Perrone F; Pignata S
    Int J Gynecol Cancer; 2022 Jun; 32(6):799-803. PubMed ID: 35318277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of recurrent ovarian cancer--a retrospective study].
    Tkácová M; Belohorská B; Sevcíková K; Hel'pianska L; Ondrus D; Ondrusová M; Spánik S
    Klin Onkol; 2010; 23(2):115-23. PubMed ID: 20465091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer.
    Harter P; Sehouli J; Vergote I; Ferron G; Reuss A; Meier W; Greggi S; Mosgaard BJ; Selle F; Guyon F; Pomel C; Lécuru F; Zang R; Avall-Lundqvist E; Kim JW; Ponce J; Raspagliesi F; Kristensen G; Classe JM; Hillemanns P; Jensen P; Hasenburg A; Ghaem-Maghami S; Mirza MR; Lund B; Reinthaller A; Santaballa A; Olaitan A; Hilpert F; du Bois A;
    N Engl J Med; 2021 Dec; 385(23):2123-2131. PubMed ID: 34874631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surgical management of recurrent ovarian cancer.
    Suh DH; Kim HS; Chang SJ; Bristow RE
    Gynecol Oncol; 2016 Aug; 142(2):357-67. PubMed ID: 27130407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of salvage cytoreductive surgery in the treatment of patients with recurrent ovarian cancer after platinum-based chemotherapy.
    Matsumoto A; Higuchi T; Yura S; Mandai M; Kariya M; Takakura K; Fujii S
    J Obstet Gynaecol Res; 2006 Dec; 32(6):580-7. PubMed ID: 17100820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial.
    Shi T; Zhu J; Feng Y; Tu D; Zhang Y; Zhang P; Jia H; Huang X; Cai Y; Yin S; Jiang R; Tian W; Gao W; Liu J; Yang H; Cheng X; Zang R
    Lancet Oncol; 2021 Apr; 22(4):439-449. PubMed ID: 33705695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytoreductive Surgery (CRS) Combined With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Platinum-Sensitive Recurrence Epithelial Ovarian Cancer With HRR Mutation: A Phase III Randomized Clinical Trial.
    Qi Y; Zhang Y; Shi Y; Yao S; Dai M; Cai H
    Technol Cancer Res Treat; 2022; 21():15330338221104565. PubMed ID: 35929135
    [No Abstract]   [Full Text] [Related]  

  • 15. Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: a retrospective MITO group study.
    Cecere SC; Musacchio L; Bartoletti M; Salutari V; Arenare L; Lorusso D; Ronzino G; Lauria R; Cormio G; Naglieri E; Scollo P; Marchetti C; Raspagliesi F; Greggi S; Cinieri S; Bergamini A; Orditura M; Valabrega G; Scambia G; Martinelli F; De Matteis E; Cardalesi C; Loizzi V; Perniola G; Carella C; Scandurra G; Giannone G; Pignata S
    Int J Gynecol Cancer; 2021 Jul; 31(7):1031-1036. PubMed ID: 33990353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Secondary cytoreductive surgery for recurrent ovarian cancer. A prospective study.
    Eisenkop SM; Friedman RL; Wang HJ
    Cancer; 1995 Nov; 76(9):1606-14. PubMed ID: 8635065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of secondary cytoreductive surgery in platinum sensitive recurrent ovarian cancer treated with upfront neoadjuvant chemotherapy and interval debulking surgery.
    Bizzarri N; Marchetti C; Conte C; Loverro M; Giudice MT; Quagliozzi L; Distefano M; Chiantera V; Scambia G; Fagotti A
    Gynecol Oncol; 2022 Jun; 165(3):453-458. PubMed ID: 35397918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secondary cytoreductive surgery in recurrent epithelial ovarian cancer: A prognostic analysis with 103 cases.
    Fan XM; Zhang J; Niu SH; Li KX; Song CZ
    Int J Surg; 2017 Feb; 38():61-66. PubMed ID: 28027999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
    Coleman RL; Brady MF; Herzog TJ; Sabbatini P; Armstrong DK; Walker JL; Kim BG; Fujiwara K; Tewari KS; O'Malley DM; Davidson SA; Rubin SC; DiSilvestro P; Basen-Engquist K; Huang H; Chan JK; Spirtos NM; Ashfaq R; Mannel RS
    Lancet Oncol; 2017 Jun; 18(6):779-791. PubMed ID: 28438473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secondary cytoreductive surgery in patients with isolated platinum-resistant recurrent ovarian cancer: a retrospective analysis.
    Petrillo M; Pedone Anchora L; Tortorella L; Fanfani F; Gallotta V; Pacciani M; Scambia G; Fagotti A
    Gynecol Oncol; 2014 Aug; 134(2):257-61. PubMed ID: 24910451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.